Amgen INC Form 4 insider transactions

Rachna Khosla, SVP, Business Development of Amgen Inc, sold 3,252 shares of common stock on August 11, 2026.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc, received 730 shares of common stock on August 7, 2026.

Omar Ishrak, a Director of Amgen Inc, received 85 shares of common stock on August 7, 2026.

Charles M Holley, a Director of Amgen Inc, received 103 shares of common stock on August 7, 2026.

Michael Drake V, a Director of Amgen Inc, received 64 shares of common stock on August 7, 2026.

Derek Miller, SVP, Human Resources of Amgen Inc, sold 3,890 shares of common stock on August 6, 2026 for $402.54 per share.

Nancy A. Grygiel, SVP & CCO of Amgen Inc, sold 2,970 shares of common stock on August 6, 2026 for $402.16 per share.

Amgen Inc. director Amy E. Miles acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. director Ellen J. Kullman acquired 665 shares of common stock through the immediate vesting of restricted stock units.

Amgen Inc. director Mary E. Klotman acquired 665 shares of common stock through an immediate vesting of restricted stock units.

Amgen Inc. director Tyler Jacks acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Omar Ishrak acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Charles M. Holley acquired 665 shares of common stock through the vesting of Restricted Stock Units.

Amgen Inc. director Greg C. Garland acquired 665 shares of common stock through the immediate vesting of restricted stock units.

Amgen Inc. director Robert Eckert acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Brian Druker acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Amgen Inc. Director Michael V. Drake acquired 665 shares of common stock through an immediate vesting of Restricted Stock Units.

Amgen Inc. Director Wanda M. Austin acquired 665 shares of common stock through the vesting of restricted stock units.

Amgen VP of Finance and CAO Matthew C. Busch reported the disposition of 41 shares of common stock to cover tax obligations.

Amgen Inc. EVP of Operations Esteban Santos reported the disposition of 522 shares of common stock to cover tax obligations.

Amgen Inc. EVP and Chief Technology Officer David M. Reese disposed of 556 shares of common stock to cover tax obligations.

Amgen Inc. SVP of Human Resources Derek Miller disposed of 151 shares of common stock to cover tax obligations.

Amgen Inc. SVP of Business Development Rachna Khosla disposed of 93 shares of common stock to cover tax obligations.

Amgen Inc. SVP and CCO Nancy A. Grygiel reported the disposition of 88 shares of common stock to cover tax obligations.

Amgen Inc. EVP and CFO Peter H. Griffith reported the disposition of 556 shares of common stock to cover tax obligations.

Amgen EVP and General Counsel Jonathan P. Graham disposed of 499 shares of common stock to cover tax obligations.

Amgen Executive Vice President Murdo Gordon disposed of 615 shares of common stock to cover tax obligations.

Amgen Chairman and CEO Robert A. Bradway reported the disposition of 2,079 shares of common stock to cover tax obligations.

Amgen Inc. EVP of Research and Development James E. Bradner disposed of 446 shares of common stock to satisfy tax withholding obligations.

Amgen's EVP of Research and Development, James Bradner, received over 25,000 equity-based awards, including stock options and restricted stock units, as part of the company's long-term incentive plan.